2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Amine N-methyltransferase
  5. NNMT Isoform

NNMT

NNMT (nicotinamide N-methyltransferase) is a cytosolic methyltransferase that transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide (NAM), generating 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH), thereby connecting NAD+ metabolism with cellular methyl-donor utilization[1][2]. Mechanistically, NNMT regulates metabolic homeostasis by influencing intracellular SAM availability, NAD+ salvage, and methylation potential, which positions the enzyme at the intersection of energy metabolism and epigenetic control[1][3][4]. NNMT-driven consumption of methyl donors can create a metabolic methylation sink that remodels histone methylation patterns and alters gene-expression programs in cancer cells[3]. In disease models, elevated NNMT expression has been associated with obesity, metabolic dysfunction, fibrosis, and multiple malignancies, whereas genetic or pharmacological suppression of NNMT improves metabolic phenotypes and modifies disease progression pathways[4][5][6]. Compared with related methyltransferases such as GNMT (glycine N-methyltransferase), which primarily regulates systemic SAM/SAH balance through glycine methylation, NNMT directly links NAM turnover to NAD+ and one-carbon metabolism, giving it a distinct role in metabolic reprogramming[2][7]. For experimental applications, selective small-molecule NNMT inhibitors and bisubstrate analogs have been developed as chemical probes to evaluate target engagement, metabolic remodeling, and therapeutic responses in cancer and metabolic disease models[6][8].

References:

NNMT Related Products (5):

Cat. No. Product Name Effect Purity
  • HY-138993A
    NNMT-IN-6 hydrochloride
    		Inhibitor 99.75%
    NNMT-IN-6 hydrochloride is a selective nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 of 1.41 μM and a Kd of 5.55 μM. NNMT-IN-6 hydrochloride exhibits selectivity over PRMT1 and NSD2. NNMT-IN-6 hydrochloride inhibits cancer cell proliferation and reduces cellular N-methylnicotinamide (MNA) production. NNMT-IN-6 hydrochloride can be used for the research of oral cancer.
  • HY-138993
    NNMT-IN-6
    		Inhibitor
    NNMT-IN-6 is a selective nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 of 1.41 μM and a Kd of 5.55 μM. NNMT-IN-6 hydrochloride exhibits selectivity over PRMT1 and NSD2. NNMT-IN-6 inhibits cancer cell proliferation and reduces cellular N-methylnicotinamide (MNA) production. NNMT-IN-6 can be used for the research of oral cancer.
  • HY-186163
    CC-410
    		Inhibitor
    CC-410 is a selective Nicotinamide N-methyltransferase (NNMT) inhibitor with a human IC50 value of 1.6 µM. CC-410 impairs terminal adipocyte differentiation via glucocorticoid signaling network deregulation, inhibits adipogenesis and lipid accumulation with time-sensitive activity limited to early adipogenesis stages. CC-410 can be used for the researches of early-onset obesity, glucocorticoid-induced obesity.
  • HY-151500C
    JBSNF-000028
    		Inhibitor
    JBSNF-00002 is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease.
  • HY-W1006754
    NNMT-IN-7
    		Inhibitor 98.0%
    NNMT-IN-7 (Compound 4e) is a NNMT inhibitor (IC50 = 505.7 µM). NNMT-IN-7 can be used in studies of metabolic and chronic diseases.